Lactobacillus paracasei for the production of conjugated linoleic acid, nutritional and pharmaceutical preparations containing it and uses thereof

Abstract

The present invention refers to a new strain belonging to the species Lactobacillus paracasei able to convert linoleic acid into conjugated linoleic acid. The present invention refers also to nutritional or food preparations and/or pharmaceutical compositions, comprising the strain Lactobacillus paracasei , useful in the treatment and/or prevention of pathologies and/or physiological states related to conjugated linoleic acid deficiency or in the cases wherein the use of a probiotic is beneficial.

1 . A bacterial strain belonging to the species  Lactobacillus paracasei  filed at the Coordinated Collection of Microorganism-BCCM/LMG Bacteria Collection, Microbiology Laboratory-Ghent University, registered with the number LMG S-26420, characterized in that it converts linoleic acid in conjugated linoleic acid in a percentage higher than 30%. 
     
     
         2 . A bacterial strain  Lactobacillus paracasei  LMG S-26420 according to  claim 1 , characterized in that it converts linoleic acid into the isomers with biological activity of conjugated linoleic acid c9-t11 e t9-t11, wherein their sum is in a percentage higher than 30% if compared to the other isomers. 
     
     
         3 . A process for the production of the strain  Lactobacillus paracasei  LMG S-26420 of  claim 1  characterized by the following steps:
 inoculating the strain  Lactobacillus paracasei  LMG S-26420 in a volumetric percentage from 0.1% to 10%, in a suitable culture medium at a temperature from 30° C. to 37° C. at pH values between 4.5 and 7.5 for a time from 6 to 15 hours; 
 separating the bacterial mass from the culture broth by centrifugation; 
 storing the bacterial mass at a temperature lower than 0° C., or lyophilising. 
 
     
     
         4 . A process for the production of the bacterial strain  Lactobacillus paracasei  LMG S-26420 according to  claim 3 , comprising the step of lyophilizing in the presence of cryoprotectants selected among soluble carbohydrates. 
     
     
         5 . A process according to  claim 4  for the production of the lyophilic bacterial strain  Lactobacillus paracasei  LMG S-26420 in the presence of trealose. 
     
     
         6 . A process according to  claim 3 , wherein the strain  Lactobacillus paracasei  LMG S-26420 is obtained with a number of colony forming units higher than 109 for millilitre of culture, and the biomass in an amount higher than 4 grams per litre of culture. 
     
     
         7 . A nutritional or food or pharmaceutical composition comprising a cell amount of the bacterial strain  Lactobacillus paracasei  LMG S-26420 from 1×108 to 5×1011, together with acceptable excipients in form of tablets, granules for sachets, capsules or liquid suspensions. 
     
     
         8 . A nutritional or food or pharmaceutical composition according to  claim 7  comprising prebiotics, vitamins, mineral salts. 
     
     
         9 . A nutritional or food or pharmaceutical composition according to  claim 8 , wherein the prebiotics are selected from the group consisting of fructo-oligosaccharides, inulines, galacto-oligosaccharides, xylo-oligosaccharides, and isomalto-oligosaccharides and the vitamins are selected from the group consisting of vitamins E and B. 
     
     
         10 . A nutritional or food or pharmaceutical composition according to  claim 7  comprising bifidobacteria. 
     
     
         11 . Method of treating or preventing pathologies or diseases related to a deficiency of conjugated linoleic acid and in all cases where a probiotic is beneficial in a subject in need thereof, said method comprising
 administering to said subject a pharmaceutical effective amount of a nutritional or food or pharmaceutical composition comprising the bacterial strain  Lactobacillus paracasei  LMG S-26420.   
     
     
         12 . Method of treating and/or preventing inflammatory diseases, intestinal inflammatory pathologies, oxidative stress, tumour, autoimmune diseases, diabetes and atherosclerosis in a subject in need thereof with a nutritional or food or pharmaceutical composition comprising the bacterial strain  Lactobacillus paracasei  LMG S-26420, said method comprising:
 administering to said subject a pharmaceutical effective amount of said nutritional or food or pharmaceutical composition comprising the bacterial strain  Lactobacillus paracasei  LMG S-26420.   
     
     
         13 . Method of treating diseases related to bacterial dysbiosis in a subject in need thereof with the nutritional or food or pharmaceutical composition according to  claim 7  comprising  lactobacilli  belonging to different strains and/or Bifidobacteria, said method comprising:
 administering to said subject a pharmaceutical effective amount of said nutritional or food or pharmaceutical. 
 
     
     
         14 . Method of increasing body mass and thermogenesis in a subject in need thereof with a nutritional or food or pharmaceutical composition comprising the bacterial strain  Lactobacillus paracasei  LMG S-26420, said method comprising:
 administering to said subject a pharmaceutical effective amount of said nutritional or food or pharmaceutical composition comprising the bacterial strain  Lactobacillus paracasei  LMG S-26420.